Login to Your Account

Chengdu Kanghong wins CFDA nod as China’s first novel MAb

By Cornelia Zou
Staff Writer

Wednesday, December 18, 2013

HONG KONG – The China Food and Drug Administration (CFDA) has approved the first novel monoclonal antibody (MAb) in China with global intellectual property rights. Compaq Sipp ophthalmic injection (conbercept), a VEGF receptor antagonist, for wet age-related macular degeneration (AMD), joins similar biologics – such as Avastin (bevacizumab) and Lucentis (ranibizumab) with blockbuster sales potential.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription